Drugs / C3BS-CQR-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02317458 | Jun 2017 → Mar 2020 | heart failure | Celyad Oncology SA | Unknown | No outcome recorded |
| Phase 3 | NCT01768702 | Nov 2012 → Aug 2017 | heart failure | Celyad Oncology SA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C3BS-CQR-1 | “EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE” NCT02317458 ↗ |
| Modality | Cell therapy | “validate cardiopoietic stem cell therapy” PMID 26662998 ↗ Dec 2015 |
| Route | Other | “administered via a retention-enhanced intramyocardial injection catheter” PMID 26662998 ↗ Dec 2015 |